Xenon Pharmaceuticals Inc.
DE ˙ DB ˙ CA98420N1050
45,60 € ↑1,00 (2,24%)
2026-06-04
AKTIENPREIS
SecurityDE:XP0 / Xenon Pharmaceuticals Inc.
InstitutionPrudential Financial Inc
Latest Disclosed Ownership13,010 shares
Latest Disclosed Value $ 756,532
Prudential Financial Inc ownership in XP0 / Xenon Pharmaceuticals Inc.

On May 13, 2026 - Prudential Financial Inc filed a 13F-HR form disclosing ownership of 13,010 shares of Xenon Pharmaceuticals Inc. (DE:XP0) valued at $624,480 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 0 shares of Xenon Pharmaceuticals Inc.. The current value of the position is $593,256 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F XENON PHARMACEUTICALS COM 98420N105 13,010 13,010 757 0.0005
2026-02-13 2025-12-31 13F XENON PHARMACEUTICALS COM 98420N105 0 -8,850 -100.00 0 -100.00
2025-11-13 2025-09-30 13F XENON PHARMACEUTICALS COM 98420N105 8,850 -38,905 -81.47 355 -76.84 0.0004
2025-08-12 2025-06-30 13F XENON PHARMACEUTICALS COM 98420N105 47,755 8,755 22.45 1,534 17.20 0.0020
2025-05-13 2025-03-31 13F XENON PHARMACEUTICALS COM 98420N105 39,000 0 0.00 1,308 -14.40 0.0019
2025-02-11 2024-12-31 13F XENON PHARMACEUTICALS COM 98420N105 39,000 24,956 177.70 1,529 176.81 0.0021
2024-11-14 2024-09-30 13F XENON PHARMACEUTICALS COM 98420N105 14,044 -37,956 -72.99 553 -72.77 0.0008
2024-08-13 2024-06-30 13F XENON PHARMACEUTICALS COM 98420N105 52,000 -7,000 -11.86 2,027 -20.17 0.0030
2024-05-14 2024-03-31 13F XENON PHARMACEUTICALS COM 98420N105 59,000 0 0.00 2,540 -6.55 0.0036
2024-02-13 2023-12-31 13F XENON PHARMACEUTICALS COM 98420N105 59,000 32,000 118.52 2,718 185.10 0.0041
2023-11-13 2023-09-30 13F XENON PHARMACEUTICALS COM 98420N105 27,000 27,000 954 0.0015
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.